Tizaterkib

N/A

Report date: 2024/07/24 20:00:37
NME

Base Information

Drug NameTizaterkib
Drug Alias NameAZD-0364ATG-017
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionExtracellular-signal-regulated kinase1 inhibitorsExtracellular-signal-regulated kinase 2 inhibitors
TargetsExtracellular-signal-regulated kinase1Extracellular-signal-regulated kinase 2
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol Myers Squibb SrlcompanyAntengene Therapeutics LtdAntengene Corporation (Shanghai) Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A